{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:06Z","timestamp":1787387046656,"version":"build-2736575974"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03644-x","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:25:34Z","timestamp":1780737934000},"page":"3945-3964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Once-Weekly Subcutaneous Semaglutide 2.4\u00a0mg Injection is Cost-Effective for Weight Management in Spain"],"prefix":"10.1007","volume":"43","author":[{"given":"Andreu","family":"Alt\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Moreno-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Sastre-Bel\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ened","family":"Rodr\u00edguez-Urgell\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"P\u00e9rez-Alc\u00e1ntara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0558-890X","authenticated-orcid":false,"given":"Alberto","family":"Mart\u00edn-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sand\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"3644_CR1","unstructured":"World Health Organization (WHO). Obesity and overweight. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 9 Feb 2026."},{"issue":"1","key":"3644_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/oby.22378","volume":"27","author":"AM Jastreboff","year":"2019","unstructured":"Jastreboff AM, Kotz CM, Kahan S, Kelly A, Heymsfield S. Obesity as a disease: the Obesity Society 2018 position statement. Obesity Silver Spring. 2019;27(1):7\u20139. https:\/\/doi.org\/10.1002\/oby.22378.","journal-title":"Obesity Silver Spring"},{"issue":"2","key":"3644_CR3","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.53435\/funj.00613","volume":"8","author":"A Lecube Torell\u00f3","year":"2022","unstructured":"Lecube Torell\u00f3 A, Freitas P, Morereo S, Souto S, Tinahones FJ. Consenso ib\u00e9rico sobre el tratamiento farmacol\u00f3gico de la obesidad en el paciente adulto: posicionamiento de las sociedades espa\u00f1ola y portuguesa para el estudio de la obesidad (seedo-speo) 2018. Rev Soc Esp Cir Obes Metab Soc Esp Estud Obes. 2022;8(2):2325\u201343. https:\/\/doi.org\/10.53435\/funj.00613.","journal-title":"Rev Soc Esp Cir Obes Metab Soc Esp Estud Obes"},{"issue":"3","key":"3644_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ecl.2016.04.004","volume":"45","author":"TK Kyle","year":"2016","unstructured":"Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45(3):511\u201320. https:\/\/doi.org\/10.1016\/j.ecl.2016.04.004.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9945","key":"3644_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","volume":"384","author":"M Ng","year":"2014","unstructured":"Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(14)60460-8.","journal-title":"Lancet"},{"key":"3644_CR6","unstructured":"World Health Organization (WHO). Obesity. 2021. https:\/\/www.who.int\/news-room\/facts-in-pictures\/detail\/6-facts-on-obesity. Accessed 9 Feb 2026."},{"key":"3644_CR7","unstructured":"Organization for Economic Cooperation and Development (OECD). Obesity Update. 2017. https:\/\/www.oecd.org\/els\/health-systems\/Obesity-Update-2017.pdf. Accessed 9 Feb 2026."},{"issue":"3","key":"3644_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.recesp.2020.12.013","volume":"75","author":"C P\u00e9rez-Rodrigo","year":"2022","unstructured":"P\u00e9rez-Rodrigo C, Herv\u00e1s B\u00e1rbara G, Gianzo Citores M, Aranceta-Bartrina J. Prevalencia de obesidad y factores de riesgo cardiovascular asociados en la poblaci\u00f3n general espa\u00f1ola: Estudio ENPE. Rev Esp Cardiol. 2022;75(3):232\u201341. https:\/\/doi.org\/10.1016\/j.recesp.2020.12.013.","journal-title":"Rev Esp Cardiol"},{"key":"3644_CR9","unstructured":"World Obesity Federation (WOF). World Obesity Atlas 2024. 2024. https:\/\/data.worldobesity.org\/publications\/?cat=22. Accessed 9 Feb 2026."},{"key":"3644_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ypmed.2010.03.016","volume":"51","author":"C Li","year":"2010","unstructured":"Li C, Ford ES, Zhao G, Croft J, Balluz L, Mokdad A. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: national health and nutrition examination survey, 2005-2006. Prev Med. 2010;51:18\u201323. https:\/\/doi.org\/10.1016\/j.ypmed.2010.03.016.","journal-title":"Prev Med"},{"issue":"16","key":"3644_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.16.1523","volume":"282","author":"A Must","year":"1999","unstructured":"Must A. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523. https:\/\/doi.org\/10.1001\/jama.282.16.1523.","journal-title":"JAMA"},{"issue":"2","key":"3644_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ene.13216","volume":"24","author":"A Rodr\u00edguez-Campello","year":"2017","unstructured":"Rodr\u00edguez-Campello A, Jim\u00e9nez-Conde J, Ois \u00c1, et al. Sex-related differences in abdominal obesity impact on ischemic stroke risk. Eur J Neurol. 2017;24(2):397\u2013403. https:\/\/doi.org\/10.1111\/ene.13216.","journal-title":"Eur J Neurol"},{"issue":"7","key":"3644_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nm.4350","volume":"23","author":"MP Czech","year":"2017","unstructured":"Czech MP. Insulin action and resistance in obesity and type\u00a02 diabetes. Nat Med. 2017;23(7):804\u201314. https:\/\/doi.org\/10.1038\/nm.4350.","journal-title":"Nat Med"},{"issue":"1","key":"3644_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","volume":"127","author":"AR Saltiel","year":"2017","unstructured":"Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1\u20134. https:\/\/doi.org\/10.1172\/JCI92035.","journal-title":"J Clin Invest"},{"issue":"5","key":"3644_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.11124\/JBISRIR-2016-002725","volume":"14","author":"L Cooper","year":"2016","unstructured":"Cooper L, Ryan C, Ells LJ, et al. Weight-loss interventions for overweight\/obese adults with chronic musculoskeletal pain. JBI Database Syst Rev Implement Rep. 2016;14(5):57\u201367. https:\/\/doi.org\/10.11124\/JBISRIR-2016-002725.","journal-title":"JBI Database Syst Rev Implement Rep"},{"issue":"4","key":"3644_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","volume":"3","author":"SS Khan","year":"2018","unstructured":"Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280. https:\/\/doi.org\/10.1001\/jamacardio.2018.0022.","journal-title":"JAMA Cardiol"},{"key":"3644_CR17","doi-asserted-by":"publisher","unstructured":"GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Eng J Med. 377(1):13\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1614362","DOI":"10.1056\/NEJMoa1614362"},{"issue":"6","key":"3644_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41366-021-00788-4","volume":"45","author":"CL Haase","year":"2021","unstructured":"Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5\u00a0million people: evidence from a UK primary care database. Int J Obes. 2021;45(6):1249\u201358. https:\/\/doi.org\/10.1038\/s41366-021-00788-4.","journal-title":"Int J Obes"},{"issue":"2","key":"3644_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pcad.2018.06.004","volume":"61","author":"ME Pich\u00e9","year":"2018","unstructured":"Pich\u00e9 ME, Poirier P, Lemieux I, Despr\u00e9s JP. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis. 2018;61(2):103\u201313. https:\/\/doi.org\/10.1016\/j.pcad.2018.06.004.","journal-title":"Prog Cardiovasc Dis"},{"issue":"11","key":"3644_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1467-789X.2010.00766.x","volume":"11","author":"A Sharma","year":"2010","unstructured":"Sharma A. A mnemonic for assessing obesity. Obes Rev. 2010;11(11):808\u20139. https:\/\/doi.org\/10.1111\/j.1467-789X.2010.00766.x.","journal-title":"Obes Rev"},{"issue":"1","key":"3644_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Pub Health. 2009;9(1):88. https:\/\/doi.org\/10.1186\/1471-2458-9-88.","journal-title":"BMC Pub Health"},{"issue":"3","key":"3644_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","volume":"67","author":"FS Luppino","year":"2010","unstructured":"Luppino FS, Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220\u20139. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.2.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"3644_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.7.824","volume":"63","author":"GE Simon","year":"2006","unstructured":"Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63(7):824. https:\/\/doi.org\/10.1001\/archpsyc.63.7.824.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"3644_CR24","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1053\/j.gastro.2006.03.019","volume":"130","author":"TS Church","year":"2006","unstructured":"Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to non-alcoholic fatty liver disease. Gastroenterology. 2006;130(7):2023\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2006.03.019.","journal-title":"Gastroenterology"},{"issue":"2","key":"3644_CR25","first-page":"A48","volume":"6","author":"AS Hosler","year":"2009","unstructured":"Hosler AS. Prevalence of self-reported prediabetes among adults participating in a community-based health awareness program, New York State. Prev Chronic Dis. 2009;6(2):A48.","journal-title":"Prev Chronic Dis"},{"issue":"1","key":"3644_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.15277\/bjd.2019.205","volume":"19","author":"D Fountain","year":"2019","unstructured":"Fountain D, Al Kharaiji M, Awad S, Hughes D, Idris I. Prevalence of co-morbidities in a specialist weight management programme prior to bariatric surgery. Br J Diabetes. 2019;19(1):8\u201313. https:\/\/doi.org\/10.15277\/bjd.2019.205.","journal-title":"Br J Diabetes"},{"key":"3644_CR27","unstructured":"Organisation for Economic Cooperation and Development (OECD). Heavy burden of obesity: the economics of prevention. 2019. https:\/\/www.oecd.org\/health\/health-systems\/Heavy-burden-of-obesity-Policy-Brief-2019.pdf. Accessed 2022 Apr 1."},{"issue":"2","key":"3644_CR28","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s12325-024-03094-3","volume":"42","author":"MD Ballesteros-Pomar","year":"2025","unstructured":"Ballesteros-Pomar MD, Rodr\u00edguez-Urgell\u00e9s E, Sastre-Bel\u00edo M, et al. Assessment of the potential clinical and economic impact of weight loss in the adult population with obesity and associated comorbidities in Spain. Adv Ther. 2025;42(2):1265\u201382. https:\/\/doi.org\/10.1007\/s12325-024-03094-3.","journal-title":"Adv Ther"},{"key":"3644_CR29","unstructured":"Pereira-Bouzas P, Vicente E, Pach\u00f3n M, Gonzalo E, Hidalgo-Vega \u00c1, Garc\u00eda E. El valor social de un mejor control en la obesidad en Espa\u00f1a. Madrid; 2025. https:\/\/www.weber.org.es\/wp-content\/uploads\/2025\/11\/Proyecto-OBESIDAD-WEB-1.pdf. Accessed 9 Feb 2026."},{"issue":"10031","key":"3644_CR30","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","volume":"387","author":"GA Bray","year":"2016","unstructured":"Bray GA, Fr\u00fchbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016;387(10031):1947\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(16)00271-3.","journal-title":"Lancet"},{"key":"3644_CR31","unstructured":"Lecube A, Azcona C, Azriel S, et al. 2a edici\u00f3n Gu\u00eda Espa\u00f1ola GIRO: gu\u00eda espa\u00f1ola del manejo integral y mul - tidisciplinar de la obesidad en personas adultas, 2025. Madrid; 2025 Apr. https:\/\/www.seedo.es\/images\/site\/giro\/GUIA-GIRO-2a-edicin_26NOV2024.pdf. Accessed 9 Feb 2026."},{"issue":"Suppl2","key":"3644_CR32","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1002\/oby.20660","volume":"22","author":"Expert panel report","year":"2014","unstructured":"Expert panel report. Guidelines (2013) for the management of overweight and obesity in adults. Obesity. 2014;22(Suppl2):S41-410. https:\/\/doi.org\/10.1002\/oby.20660.","journal-title":"Obesity"},{"issue":"3","key":"3644_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ahj.2005.03.003","volume":"151","author":"G Foster","year":"2006","unstructured":"Foster G. The behavioral approach to treating obesity. Am Heart J. 2006;151(3):625\u20137. https:\/\/doi.org\/10.1016\/j.ahj.2005.03.003.","journal-title":"Am Heart J"},{"key":"3644_CR34","unstructured":"World Health Organization (WHO). WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults. Geneva; 2025 Dec. https:\/\/files.magicapp.org\/guideline\/6536c5ab-d6c8-4908-8a4c-0189ef096766\/published_guideline_10807-1_1.pdf. Accessed 9 Feb 2026."},{"key":"3644_CR35","unstructured":"European Medicines Agency (EMA). Ficha t\u00e9cnica semaglutida 2,4mg. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_es.pdf. Accessed 2022 Mar 22."},{"issue":"11","key":"3644_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMOA2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMOA2032183.","journal-title":"N Engl J Med"},{"issue":"10278","key":"3644_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type\u00a02 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase\u00a03 trial. Lancet. 2021;397(10278):971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","journal-title":"Lancet"},{"issue":"14","key":"3644_CR38","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/JAMA.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313. https:\/\/doi.org\/10.1001\/JAMA.2021.1831.","journal-title":"JAMA"},{"issue":"14","key":"3644_CR39","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/JAMA.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325. https:\/\/doi.org\/10.1001\/JAMA.2021.3224.","journal-title":"JAMA"},{"issue":"12","key":"3644_CR40","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"issue":"24","key":"3644_CR41","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2208601.","journal-title":"N Engl J Med"},{"issue":"3","key":"3644_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type\u00a02 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase\u00a03a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206. https:\/\/doi.org\/10.1016\/S2213-8587(22)00008-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3644_CR43","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/S41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083. https:\/\/doi.org\/10.1038\/S41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"2","key":"3644_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/JAMA.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/JAMA.2021.23619.","journal-title":"JAMA"},{"issue":"3","key":"3644_CR45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu Y, Bao X, Eliaschewitz FG, et al. Efficacy and safety of once weekly semaglutide 2\u00b74\u00a0mg for weight management in a predominantly East Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12(3):184\u201395. https:\/\/doi.org\/10.1016\/S2213-8587(23)00388-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"3644_CR46","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type\u00a02 diabetes. N Engl J Med. 2024;390(15):1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917.","journal-title":"N Engl J Med"},{"issue":"9","key":"3644_CR47","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2\u00b74\u00a0mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase\u00a03 trial. Lancet Diabetes Endocrinol. 2024;12(9):631\u201342. https:\/\/doi.org\/10.1016\/S2213-8587(24)00182-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"3644_CR48","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"10","key":"3644_CR49","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S2213-8587(25)00164-0","volume":"13","author":"S Lim","year":"2025","unstructured":"Lim S, Buranapin S, Bao X, et al. Once-weekly semaglutide 2\u00b74\u00a0mg in an Asian population with obesity, defined as BMI \u226525\u00a0kg\/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Diabetes Endocrinol. 2025;13(10):838\u201347. https:\/\/doi.org\/10.1016\/S2213-8587(25)00164-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"3644_CR50","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2403664.","journal-title":"N Engl J Med"},{"issue":"11","key":"3644_CR51","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, et al. Once-weekly semaglutide 7\u00b72\u00a0mg in adults with obesity (STEP UP): a randomised, controlled, phase\u00a03b trial. Lancet Diabetes Endocrinol. 2025;13(11):949\u201363. https:\/\/doi.org\/10.1016\/S2213-8587(25)00226-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"3644_CR52","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase\u00a03 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"1","key":"3644_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40273-024-01441-4","volume":"43","author":"L Vallejo-Torres","year":"2025","unstructured":"Vallejo-Torres L. Estimating the incremental cost per QALY produced by the Spanish NHS: a fixed-effect econometric approach. Pharmacoeconomics. 2025;43(1):109\u201322. https:\/\/doi.org\/10.1007\/s40273-024-01441-4.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"3644_CR54","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40273-020-00941-3","volume":"38","author":"S Lopes","year":"2020","unstructured":"Lopes S, Johansen P, Lamotte M, McEwan P, Olivieri AV, Foos V. External validation of the Core Obesity Model to assess the cost-effectiveness of weight management interventions. Pharmacoeconomics. 2020;38(10):1123\u201333. https:\/\/doi.org\/10.1007\/s40273-020-00941-3.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"3644_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/osp4.495","volume":"7","author":"S Lopes","year":"2021","unstructured":"Lopes S, Meincke HH, Lamotte M, Olivieri A, Lean MEJ. A novel decision model to predict the impact of weight management interventions: The Core Obesity Model. Obes Sci Pract. 2021;7(3):269\u201380. https:\/\/doi.org\/10.1002\/osp4.495.","journal-title":"Obes Sci Pract"},{"key":"3644_CR56","unstructured":"European Medicines Agency (EMA). Guideline on clinical evaluation of medicinal products used in weight management. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-medicinal-products-used-weight-management-revision-1_en.pdf. Accessed 2026 Apr 29."},{"issue":"6","key":"3644_CR57","doi-asserted-by":"publisher","first-page":"267.e1","DOI":"10.1016\/J.MEDCLI.2019.10.014","volume":"155","author":"A Caix\u00e0s","year":"2020","unstructured":"Caix\u00e0s A, Villar\u00f3 M, Arraiza C, et al. SEEDO-SEMERGEN consensus document on continuous care of obesity between Primary Care and Specialist Hospital Units 2019. Med Clin (Barc). 2020;155(6):267.e1-267.e11. https:\/\/doi.org\/10.1016\/J.MEDCLI.2019.10.014.","journal-title":"Med Clin (Barc)"},{"key":"3644_CR58","unstructured":"US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Obesity and Overweight: developing Drugs and Biological Products for Weight Reduction. Guidance for Industry. 2025 Jan. https:\/\/www.fda.gov\/media\/71252\/download. Accessed 9 Feb 2026."},{"issue":"11","key":"3644_CR59","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","volume":"31","author":"K Nadolsky","year":"2025","unstructured":"Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease \u2013 2025 update. Endocr Pract. 2025;31(11):1351\u201394. https:\/\/doi.org\/10.1016\/j.eprac.2025.07.017.","journal-title":"Endocr Pract"},{"issue":"8","key":"3644_CR60","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","journal-title":"Diabetes Obes Metab"},{"key":"3644_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099","volume":"23","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;23:j2099. https:\/\/doi.org\/10.1136\/bmj.j2099.","journal-title":"BMJ"},{"issue":"9","key":"3644_CR62","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type\u00a02 diabetes mellitus using data from the 30\u00a0year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925\u201333. https:\/\/doi.org\/10.1007\/s00125-013-2940-y.","journal-title":"Diabetologia"},{"key":"3644_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5019","volume":"20","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type\u00a02 diabetes: cohort study. BMJ. 2017;20:j5019.","journal-title":"BMJ"},{"issue":"8","key":"3644_CR64","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/ARCHINTE.162.8.893","volume":"162","author":"T Young","year":"2002","unstructured":"Young T, Shahar E, Nieto FJ, Redline S, Newman AB, Gottlieb DJ. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med. 2002;162(8):893\u2013900. https:\/\/doi.org\/10.1001\/ARCHINTE.162.8.893.","journal-title":"Arch Intern Med"},{"issue":"4","key":"3644_CR65","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0749-3797(03)00218-6","volume":"25","author":"AM Wendelboe","year":"2003","unstructured":"Wendelboe AM, Hegmann KT, Biggs JJ, et al. Relationships between body mass indices and surgical replacements of knee and hip joints. Am J Prev Med. 2003;25(4):290\u20135. https:\/\/doi.org\/10.1016\/S0749-3797(03)00218-6.","journal-title":"Am J Prev Med"},{"key":"3644_CR66","unstructured":"Ministerio de Sanidad. Portal Estad\u00edstico. Registro de Actividad de Atenci\u00f3n Especializada - RAE-CMBD. 2023. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/N\/rae-cmbd\/rae-cmbd. Accessed 2023 Jan 6."},{"issue":"6","key":"3644_CR67","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/dom.15546","volume":"26","author":"XW Luah","year":"2024","unstructured":"Luah XW, Holst-Hansen T, L\u00fcbker C. The association between body mass index and health-related quality of life in the 2017 and 2018\u00a0health survey of England data: a cross-sectional observational analysis. Diabetes Obes Metab. 2024;26(6):2318\u201328. https:\/\/doi.org\/10.1111\/dom.15546.","journal-title":"Diabetes Obes Metab"},{"key":"3644_CR68","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Fen\u00f3menos demogr\u00e1ficos. Tablas de mortalidad. 2025. https:\/\/ine.es\/jaxiT3\/Tabla.htm?t=27153. Accessed 9 Feb 2026."},{"key":"3644_CR69","unstructured":"World Health Organization (WHO). WHO Mortality Database. 2025. https:\/\/www.who.int\/data\/data-collection-tools\/who-mortality-database. Accessed 9 Feb 2026."},{"issue":"12","key":"3644_CR70","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","volume":"6","author":"K Bhaskaran","year":"2018","unstructured":"Bhaskaran K, dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3\u00b76\u00a0million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944\u201353. https:\/\/doi.org\/10.1016\/S2213-8587(18)30288-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"3644_CR71","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.recesp.2017.10.019","volume":"71","author":"G V\u00e1zquez-Oliva","year":"2018","unstructured":"V\u00e1zquez-Oliva G, Zamora A, Ramos R, et al. Tasas de incidencia y mortalidad, y letalidad poblacional a 28 d\u00edas del infarto agudo de miocardio en adultos mayores. Estudio REGICOR. Rev Esp Cardiol. 2018;71(9):718\u201325. https:\/\/doi.org\/10.1016\/j.recesp.2017.10.019.","journal-title":"Rev Esp Cardiol"},{"issue":"4","key":"3644_CR72","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10198-016-0799-9","volume":"18","author":"J Alvarez-Sab\u00edn","year":"2017","unstructured":"Alvarez-Sab\u00edn J, Quintana M, Masjuan J, et al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. 2017;18(4):449\u201358. https:\/\/doi.org\/10.1007\/s10198-016-0799-9.","journal-title":"Eur J Health Econ"},{"issue":"12","key":"3644_CR73","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1136\/ard.2010.148726","volume":"70","author":"JA Singh","year":"2011","unstructured":"Singh JA, Jensen MR, Harmsen WS, Gabriel SE, Lewallen DG. Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty. Ann Rheum Dis. 2011;70(12):2082\u20138. https:\/\/doi.org\/10.1136\/ard.2010.148726.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3644_CR74","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/aje\/kwm049","volume":"166","author":"KF Adams","year":"2007","unstructured":"Adams KF, Leitzmann MF, Albanes D, et al. Body mass and colorectal cancer risk in the NIH-AARP Cohort. Am J Epidemiol. 2007;166(1):36\u201345. https:\/\/doi.org\/10.1093\/aje\/kwm049.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"3644_CR75","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/bjc.2012.229","volume":"107","author":"TYO Yang","year":"2012","unstructured":"Yang TYO, Cairns BJ, Allen N, Sweetland S, Reeves GK, Beral V. Postmenopausal endometrial cancer risk and body size in early life and middle age: prospective cohort study. Br J Cancer. 2012;107(1):169\u201375. https:\/\/doi.org\/10.1038\/bjc.2012.229.","journal-title":"Br J Cancer"},{"issue":"9612","key":"3644_CR76","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(08)60269-X.","journal-title":"Lancet"},{"issue":"1","key":"3644_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01338-4","volume":"16","author":"L Silva Miguel","year":"2024","unstructured":"Silva Miguel L, Soares M, Olivieri A, et al. Cost-effectiveness of semaglutide 2.4\u00a0mg in chronic weight management in Portugal. Diabetol Metab Syndr. 2024;16(1):97. https:\/\/doi.org\/10.1186\/s13098-024-01338-4.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"3644_CR78","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s12325-022-02423-8","volume":"40","author":"H Sandhu","year":"2023","unstructured":"Sandhu H, Xu W, Olivieri AV, L\u00fcbker C, Smith I, Antavalis V. Once-weekly subcutaneous semaglutide 2.4\u00a0mg injection is cost-effective for weight management in the United Kingdom. Adv Ther. 2023;40(3):1282\u201391. https:\/\/doi.org\/10.1007\/s12325-022-02423-8.","journal-title":"Adv Ther"},{"key":"3644_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. https:\/\/doi.org\/10.1136\/bmj-2025-085304.","journal-title":"BMJ"},{"key":"3644_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103796","volume":"93","author":"B Budini","year":"2026","unstructured":"Budini B, Luo S, Tam M, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. EClinicalMedicine. 2026;93:103796. https:\/\/doi.org\/10.1016\/j.eclinm.2026.103796.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"3644_CR81","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/joim.12012","volume":"273","author":"L Sj\u00f6str\u00f6m","year":"2013","unstructured":"Sj\u00f6str\u00f6m L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219\u201334. https:\/\/doi.org\/10.1111\/joim.12012.","journal-title":"J Intern Med"},{"issue":"11","key":"3644_CR82","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"E Gregg","year":"2016","unstructured":"The Look AHEAD Research Group, Gregg E, Jakicic J, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type\u00a02 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913\u201321. https:\/\/doi.org\/10.1016\/S2213-8587(16)30162-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3644_CR83","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1183\/09031936.00022111","volume":"38","author":"NS Marshall","year":"2011","unstructured":"Marshall NS, Delling L, Grunstein RR, et al. Self-reported sleep apnoea and mortality in patients from the Swedish Obese Subjects study. Eur Respir J. 2011;38(6):1349\u201354. https:\/\/doi.org\/10.1183\/09031936.00022111.","journal-title":"Eur Respir J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03644-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03644-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03644-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:53Z","timestamp":1787385893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03644-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3644"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03644-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study and manuscript have been promoted by Novo Nordisk Pharma SA. Alberto Mart\u00edn-Lorenzo is an employee of Novo Nordisk Pharma SA and Sara Larsen is an employee of Novo Nordisk A\/S. Ferran P\u00e9rez-Alc\u00e1ntara, Ened Rodr\u00edguez-Urgell\u00e9s and Miquel Sastre-Bel\u00edo are employees of Cencora Pharmalex Spain, which has received a consulting fee from Novo Nordisk Pharma SA. Andreu Alt\u00e9s reports (a) honoraria for lectures from AstraZeneca, Esteve, Lilly, Gebro, Sankyo-Daichii, Glaxo, Novo Nordisk, Sanofi and Boheringer Ingelheim; (b) consulting fees from Novo Nordisk and Lilly. \u00d3scar Moreno-P\u00e9rez reports (a) honoraria for lectures from AstraZeneca, Novo Nordisk, Bayer and Lilly; (b) consulting fees from AstraZeneca and Sanofi. Miriam Sand\u00edn reports (a) honoraria for lectures from AstraZeneca, Ferrer, Novo Nordisk, Sanofi and Amgen; (b) consulting fees from AstraZeneca, Ferrer, Amgen, Novo Nordisk and Daiichi Sankyo. Josep Vidal reports (a) honoraria for lectures from Boehringer Ingelheim, Novo Nordisk and Lilly; (b) consulting fees from Novo Nordisk and Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors have not received any payment for the authorship of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}